# Long-term Study of Asenapine in Participants With Residual Subtype, Receiving Multiple or/and High Dose Drugs, or Treatment Refractory Schizophrenia (P06238)

> **NCT01244828** · PHASE3 · COMPLETED · sponsor: **Organon and Co** · enrollment: 157 (actual)

## Conditions studied

- Schizophrenia

## Interventions

- **DRUG:** Asenapine

## Key facts

- **NCT ID:** NCT01244828
- **Lead sponsor:** Organon and Co
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04-05
- **Primary completion:** 2014-08-21
- **Final completion:** 2014-08-21
- **Target enrollment:** 157 (ACTUAL)
- **Last updated:** 2024-05-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01244828

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01244828, "Long-term Study of Asenapine in Participants With Residual Subtype, Receiving Multiple or/and High Dose Drugs, or Treatment Refractory Schizophrenia (P06238)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01244828. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*